Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

Human myeloperoxidase (hMPO) is expressed in neurons in the substantia nigra in Parkinson's disease and in the hMPO-α-synuclein-A53T mouse model, correlating with increased nitration and aggregation of α-synuclein and exacerbation of motor impairment.

Maki RA, Holzer M, Motamedchaboki K, Malle E, Masliah E, Marsche G, Reynolds WF.

Free Radic Biol Med. 2019 Sep;141:115-140. doi: 10.1016/j.freeradbiomed.2019.05.033. Epub 2019 Jun 6.

PMID:
31175983
2.

Myeloperoxidase-catalyzed oxidation of cyanide to cyanate: A potential carbamylation route involved in the formation of atherosclerotic plaques?

Delporte C, Zouaoui Boudjeltia K, Furtmüller PG, Maki RA, Dieu M, Noyon C, Soudi M, Dufour D, Coremans C, Nuyens V, Reye F, Rousseau A, Raes M, Moguilevsky N, Vanhaeverbeek M, Ducobu J, Nève J, Robaye B, Vanhamme L, Reynolds WF, Obinger C, Van Antwerpen P.

J Biol Chem. 2018 Apr 27;293(17):6374-6386. doi: 10.1074/jbc.M117.801076. Epub 2018 Mar 1.

4.

Thiocyanate supplementation decreases atherosclerotic plaque in mice expressing human myeloperoxidase.

Morgan PE, Laura RP, Maki RA, Reynolds WF, Davies MJ.

Free Radic Res. 2015 Jun;49(6):743-9. doi: 10.3109/10715762.2015.1019347. Epub 2015 Mar 27.

5.

Association of myeloperoxidase with ovarian cancer.

Castillo-Tong DC, Pils D, Heinze G, Braicu I, Sehouli J, Reinthaller A, Schuster E, Wolf A, Watrowski R, Maki RA, Zeillinger R, Reynolds WF.

Tumour Biol. 2014 Jan;35(1):141-8. doi: 10.1007/s13277-013-1017-3. Epub 2013 Jul 27.

6.

Reproductive physiology of a humanized GnRH receptor mouse model: application in evaluation of human-specific analogs.

Tello JA, Kohout T, Pineda R, Maki RA, Scott Struthers R, Millar RP.

Am J Physiol Endocrinol Metab. 2013 Jul 1;305(1):E67-77. doi: 10.1152/ajpendo.00624.2012. Epub 2013 Apr 30.

7.

Aberrant expression of myeloperoxidase in astrocytes promotes phospholipid oxidation and memory deficits in a mouse model of Alzheimer disease.

Maki RA, Tyurin VA, Lyon RC, Hamilton RL, DeKosky ST, Kagan VE, Reynolds WF.

J Biol Chem. 2009 Jan 30;284(5):3158-69. doi: 10.1074/jbc.M807731200. Epub 2008 Dec 5.

8.

Pillars article: the macrophage and B cell-specific transcription factor PU.1 is related to the ets oncogene. Cell, 1990. 61: 113-124.

Klemsz MJ, McKercher SR, Celada A, Van Beveren C, Maki RA.

J Immunol. 2008 Aug 1;181(3):1597-608. No abstract available.

9.

Human endometriosis is associated with plasma cells and overexpression of B lymphocyte stimulator.

Hever A, Roth RB, Hevezi P, Marin ME, Acosta JA, Acosta H, Rojas J, Herrera R, Grigoriadis D, White E, Conlon PJ, Maki RA, Zlotnik A.

Proc Natl Acad Sci U S A. 2007 Jul 24;104(30):12451-6. Epub 2007 Jul 17.

10.

NMR structural characterization of a minimal peptide antagonist bound to the extracellular domain of the corticotropin-releasing factor1 receptor.

Mesleh MF, Shirley WA, Heise CE, Ling N, Maki RA, Laura RP.

J Biol Chem. 2007 Mar 2;282(9):6338-46. Epub 2006 Dec 27.

11.

Histamine induces interleukin-6 expression in the human synovial sarcoma cell line (SW982) through the H1 receptor.

Wang SL, Malany S, Wang Q, Santos MA, Crowe PD, Maki RA.

Inflamm Res. 2006 Sep;55(9):393-8.

PMID:
17122961
12.

Pharmacological characterization of a novel nonpeptide antagonist of the human gonadotropin-releasing hormone receptor, NBI-42902.

Struthers RS, Xie Q, Sullivan SK, Reinhart GJ, Kohout TA, Zhu YF, Chen C, Liu XJ, Ling N, Yang W, Maki RA, Bonneville AK, Chen TK, Bozigian HP.

Endocrinology. 2007 Feb;148(2):857-67. Epub 2006 Nov 9.

PMID:
17095587
13.

Manipulation of small-molecule inhibitory kinetics modulates MCH-R1 function.

Schwarz DA, Allen MM, Petroski RE, Pomeroy JE, Heise CE, Mistry MS, Selkirk JV, Nottebaum LM, Grey J, Zhang M, Goodfellow VS, Maki RA.

Mol Cell Endocrinol. 2006 Oct 19;259(1-2):1-9. Epub 2006 Sep 20.

PMID:
16987592
14.

Experimental autoimmune encephalomyelitis develops in CC chemokine receptor 7-deficient mice with altered T-cell responses.

Pahuja A, Maki RA, Hevezi PA, Chen A, Verge GM, Lechner SM, Roth RB, Zlotnik A, Alleva DG.

Scand J Immunol. 2006 Oct;64(4):361-9.

15.

Dimerization of the melanocortin 4 receptor: a study using bioluminescence resonance energy transfer.

Nickolls SA, Maki RA.

Peptides. 2006 Feb;27(2):380-7. Epub 2006 Jan 6.

PMID:
16406142
16.

Immunomodulation in type 1 diabetes by NBI-6024, an altered peptide ligand of the insulin B epitope.

Alleva DG, Maki RA, Putnam AL, Robinson JM, Kipnes MS, Dandona P, Marks JB, Simmons DL, Greenbaum CJ, Jimenez RG, Conlon PJ, Gottlieb PA.

Scand J Immunol. 2006 Jan;63(1):59-69.

17.

A point mutation in the human melanin concentrating hormone receptor 1 reveals an important domain for cellular trafficking.

Fan J, Perry SJ, Gao Y, Schwarz DA, Maki RA.

Mol Endocrinol. 2005 Oct;19(10):2579-90. Epub 2005 May 31.

PMID:
15928315
18.

Functional selectivity of melanocortin 4 receptor peptide and nonpeptide agonists: evidence for ligand-specific conformational states.

Nickolls SA, Fleck B, Hoare SR, Maki RA.

J Pharmacol Exp Ther. 2005 Jun;313(3):1281-8. Epub 2005 Mar 2.

PMID:
15743921
19.

Distinct conformations of the corticotropin releasing factor type 1 receptor adopted following agonist and antagonist binding are differentially regulated.

Perry SJ, Junger S, Kohout TA, Hoare SR, Struthers RS, Grigoriadis DE, Maki RA.

J Biol Chem. 2005 Mar 25;280(12):11560-8. Epub 2005 Jan 14.

20.

Interleukin-4 receptor cytotoxin as therapy for human malignant pleural mesothelioma xenografts.

Beseth BD, Cameron RB, Leland P, You L, Varricchio F, Kreitman RJ, Maki RA, Jablons DM, Husain SR, Puri RK.

Ann Thorac Surg. 2004 Aug;78(2):436-43; discussion 436-43.

PMID:
15276492
21.

Cuttine edge: diabetes-associated quantitative trait locus, Idd4, is responsible for the IL-12p40 overexpression defect in nonobese diabetic (NOD) mice.

Simpson PB, Mistry MS, Maki RA, Yang W, Schwarz DA, Johnson EB, Lio FM, Alleva DG.

J Immunol. 2003 Oct 1;171(7):3333-7.

22.

Differential kinetics of hypocretins in the cerebrospinal fluid after intracerebroventricular administration in rats.

Yoshida Y, Fujiki N, Maki RA, Schwarz D, Nishino S.

Neurosci Lett. 2003 Aug 7;346(3):182-6.

PMID:
12853114
23.

Molecular determinants of melanocortin 4 receptor ligand binding and MC4/MC3 receptor selectivity.

Nickolls SA, Cismowski MI, Wang X, Wolff M, Conlon PJ, Maki RA.

J Pharmacol Exp Ther. 2003 Mar;304(3):1217-27.

PMID:
12604699
24.

Interleukin 4 receptor on human lung cancer: a molecular target for cytotoxin therapy.

Kawakami M, Kawakami K, Stepensky VA, Maki RA, Robin H, Muller W, Husain SR, Puri RK.

Clin Cancer Res. 2002 Nov;8(11):3503-11.

25.

Identification of three genes up-regulated in PU.1 rescued monocytic precursor cells.

Henkel GW, McKercher SR, Maki RA.

Int Immunol. 2002 Jul;14(7):723-32.

PMID:
12096031
26.

Identification of differentially expressed genes induced by transient ischemic stroke.

Schwarz DA, Barry G, Mackay KB, Manu F, Naeve GS, Vana AM, Verge G, Conlon PJ, Foster AC, Maki RA.

Brain Res Mol Brain Res. 2002 May 30;101(1-2):12-22.

PMID:
12007827
27.

Expression and regulation of aggrecanase in arthritis: the role of TGF-beta.

Yamanishi Y, Boyle DL, Clark M, Maki RA, Tortorella MD, Arner EC, Firestein GS.

J Immunol. 2002 Feb 1;168(3):1405-12.

28.

Interleukin 4 receptor-directed cytotoxin therapy for human head and neck squamous cell carcinoma in animal models.

Strome SE, Kawakami K, Alejandro D, Voss S, Kasperbauer JL, Salomao D, Chen L, Maki RA, Puri RK.

Clin Cancer Res. 2002 Jan;8(1):281-6.

29.

Regulation of the PU.1 gene by distal elements.

Li Y, Okuno Y, Zhang P, Radomska HS, Chen H, Iwasaki H, Akashi K, Klemsz MJ, McKercher SR, Maki RA, Tenen DG.

Blood. 2001 Nov 15;98(10):2958-65.

PMID:
11698277
30.

Identification and functional analysis of mutations in the hypocretin (orexin) genes of narcoleptic canines.

Hungs M, Fan J, Lin L, Lin X, Maki RA, Mignot E.

Genome Res. 2001 Apr;11(4):531-9.

31.

Expression and activity of ADAMTS-5 in synovium.

Vankemmelbeke MN, Holen I, Wilson AG, Ilic MZ, Handley CJ, Kelner GS, Clark M, Liu C, Maki RA, Burnett D, Buttle DJ.

Eur J Biochem. 2001 Mar;268(5):1259-68.

32.

Turning blood into brain: cells bearing neuronal antigens generated in vivo from bone marrow.

Mezey E, Chandross KJ, Harta G, Maki RA, McKercher SR.

Science. 2000 Dec 1;290(5497):1779-82.

33.

Mesenchymal cells engulf and clear apoptotic footplate cells in macrophageless PU.1 null mouse embryos.

Wood W, Turmaine M, Weber R, Camp V, Maki RA, McKercher SR, Martin P.

Development. 2000 Dec;127(24):5245-52.

34.

ADAMTS9, a novel member of the ADAM-TS/ metallospondin gene family.

Clark ME, Kelner GS, Turbeville LA, Boyer A, Arden KC, Maki RA.

Genomics. 2000 Aug 1;67(3):343-50.

PMID:
10936055
35.

Characterization of gamma-aminobutyric acid receptor GABAB(1e), a GABAB(1) splice variant encoding a truncated receptor.

Schwarz DA, Barry G, Eliasof SD, Petroski RE, Conlon PJ, Maki RA.

J Biol Chem. 2000 Oct 13;275(41):32174-81. Erratum in: J Biol Chem 2001 Mar 23;276(12):9582.

36.

Transcription factor PU.1 is necessary for development of thymic and myeloid progenitor-derived dendritic cells.

Anderson KL, Perkin H, Surh CD, Venturini S, Maki RA, Torbett BE.

J Immunol. 2000 Feb 15;164(4):1855-61.

37.

The copper transport protein Atox1 promotes neuronal survival.

Kelner GS, Lee M, Clark ME, Maciejewski D, McGrath D, Rabizadeh S, Lyons T, Bredesen D, Jenner P, Maki RA.

J Biol Chem. 2000 Jan 7;275(1):580-4.

38.

The transcription factor PU.1 does not regulate lineage commitment but has lineage-specific effects.

McKercher SR, Henkel GW, Maki RA.

J Leukoc Biol. 1999 Nov;66(5):727-32. Review.

PMID:
10577501
39.

Nephroblastoma overexpressed gene (NOV) codes for a growth factor that induces protein tyrosine phosphorylation.

Liu C, Liu XJ, Crowe PD, Kelner GS, Fan J, Barry G, Manu F, Ling N, De Souza EB, Maki RA.

Gene. 1999 Oct 1;238(2):471-8.

PMID:
10570975
40.

Mutants of ETS domain PU.1 and GGAA/T recognition: free energies and kinetics.

Pio F, Assa-Munt N, Yguerabide J, Maki RA.

Protein Sci. 1999 Oct;8(10):2098-109.

41.

PU.1 and the granulocyte- and macrophage colony-stimulating factor receptors play distinct roles in late-stage myeloid cell differentiation.

Anderson KL, Smith KA, Perkin H, Hermanson G, Anderson CG, Jolly DJ, Maki RA, Torbett BE.

Blood. 1999 Oct 1;94(7):2310-8.

PMID:
10498603
42.

Differentiation of the mononuclear phagocyte system during mouse embryogenesis: the role of transcription factor PU.1.

Lichanska AM, Browne CM, Henkel GW, Murphy KM, Ostrowski MC, McKercher SR, Maki RA, Hume DA.

Blood. 1999 Jul 1;94(1):127-38.

PMID:
10381505
43.

Commitment to the monocytic lineage occurs in the absence of the transcription factor PU.1.

Henkel GW, McKercher SR, Leenen PJ, Maki RA.

Blood. 1999 May 1;93(9):2849-58.

PMID:
10216079
44.

Mutation analysis of the Pip interaction domain reveals critical residues for protein-protein interactions.

Ortiz MA, Light J, Maki RA, Assa-Munt N.

Proc Natl Acad Sci U S A. 1999 Mar 16;96(6):2740-5.

45.

Myeloperoxidase polymorphism is associated with gender specific risk for Alzheimer's disease.

Reynolds WF, Rhees J, Maciejewski D, Paladino T, Sieburg H, Maki RA, Masliah E.

Exp Neurol. 1999 Jan;155(1):31-41.

PMID:
9918702
46.

Subtractive hybridization of cDNA libraries.

Kelner GS, Maki RA.

Methods Mol Med. 1999;22:37-44. doi: 10.1385/0-89603-612-X:37.

PMID:
21380821
47.

Murine GBP-2: a new IFN-gamma-induced member of the GBP family of GTPases isolated from macrophages.

Vestal DJ, Buss JE, McKercher SR, Jenkins NA, Copeland NG, Kelner GS, Asundi VK, Maki RA.

J Interferon Cytokine Res. 1998 Nov;18(11):977-85.

PMID:
9858320
48.

Neutrophils deficient in PU.1 do not terminally differentiate or become functionally competent.

Anderson KL, Smith KA, Pio F, Torbett BE, Maki RA.

Blood. 1998 Sep 1;92(5):1576-85.

PMID:
9716585
49.

Myeloid development is selectively disrupted in PU.1 null mice.

Anderson KL, Smith KA, Conners K, McKercher SR, Maki RA, Torbett BE.

Blood. 1998 May 15;91(10):3702-10.

PMID:
9573007
50.

Defective trophoblast function in mice with a targeted mutation of Ets2.

Yamamoto H, Flannery ML, Kupriyanov S, Pearce J, McKercher SR, Henkel GW, Maki RA, Werb Z, Oshima RG.

Genes Dev. 1998 May 1;12(9):1315-26.

Supplemental Content

Support Center